Fluidiconic Bio, a promising startup hailing from Hsinchu, Taiwan, is set to make its entrance into the American market. This May, the company will showcase its innovative tumor-on-a-chip platform at the Plug and Play Silicon Valley Summit, joining four other Taiwanese startups. The founders of Fluidiconic Bio are confident that their technology can achieve what decades of animal testing have failed to do: provide a detailed understanding of how cancer drugs operate within human tumors. This capability aims to enhance decision-making for pharmaceutical teams before they venture into clinical trials.
Transitioning from Academia to Startup Success
At the helm of Fluidiconic Bio is CEO Steven Mu, who holds a Ph.D. in chemical engineering from National Tsing Hua University (NTHU), one of Taiwan’s premier research institutions. Mu’s journey into the startup world was a gradual process. Prior to officially launching the company last year, his team spent over three years developing their core technology through government-funded research programs, including the Industrial Technology Research Institute’s (ITRI) Tree initiative. This support provided a crucial foundation, allowing the team to focus on product development without the immediate pressure of generating revenue. “Once we left to form the company,” Mu explains, “it became much easier to transition into the market.”
The primary audience for Fluidiconic Bio’s innovations includes pharmaceutical developers, hospitals, and academic research institutions. Mu succinctly articulates their mission: to assist drug developers in determining, at the preclinical stage, which drugs and dosages are effective for specific patient populations while ensuring safety. This nuanced approach addresses a critical gap that many preclinical platforms do not cover.
Addressing the Limitations of Traditional Testing
The pharmaceutical industry has long relied on animal models, particularly mice, for preclinical drug testing—a practice that has persisted for nearly eight decades. However, the limitations of this method are well-recognized: mouse biology often fails to accurately predict human responses, leading to high failure rates for drugs that pass animal trials but falter in human clinical trials.
In the early 2000s, organ-on-a-chip technology emerged as a potential solution. By leveraging advancements in microfabrication and injection molding, researchers began creating miniaturized devices populated with living human cells to mimic physiological environments. The aim was to generate more relevant data earlier in the drug development process.
Fluidiconic Bio’s platform, however, does not seek to entirely replace animal testing. Instead, it serves as a precision decision-support tool, generating more nuanced data that enhances existing workflows and helps drug developers refine their candidate selections before committing to expensive late-stage studies.
The Importance of Tumor Heterogeneity
One significant gap that Fluidiconic Bio addresses is the intratumoral heterogeneity of cancer. Tumors are not homogeneous entities; they are complex ecosystems with varying microenvironments throughout their structure. “Every position within a tumor is different,” Mu notes. “Some cells are closer to blood vessels, while others are farther away. Some divide quickly, while others do so slowly.” This variability can lead to localized resistance to treatment, where only certain regions of the tumor develop resistance to a drug, complicating treatment efficacy. If preclinical screening cannot identify these patterns, drug developers may proceed with candidates that do not provide a complete understanding of their effectiveness.
MedSelect: A Cutting-Edge Solution for Drug Development
Fluidiconic Bio’s flagship platform, MedSelect, combines a proprietary 3D co-culture chip architecture with automated, mid-throughput workflows tailored for early-stage drug development. At this stage, drug programs often manage 20 to 30 candidate compounds simultaneously. MedSelect is designed to efficiently handle this volume without compromising data quality.
One of its standout features is the ability to support up to 144 independent samples per run, far exceeding the capacity of comparable organ-chip platforms. However, Mu emphasizes that reproducibility is even more critical; the 144 samples can produce results with high consistency, leading to stronger statistical confidence for pharmaceutical companies. “We can tell a pharma company, with greater certainty, whether something works or not,” he asserts.
The platform is also adaptable for next-generation drug modalities, such as immunotherapies and cell therapies, which often involve complex biological interactions that traditional 2D cultures or animal models cannot adequately capture. MedSelect’s 3D tumor microenvironment is meticulously designed to reflect these complexities.
The Strategic Location in Hsinchu
Fluidiconic Bio’s headquarters in Hsinchu, known for its semiconductor industry and home to TSMC, provides unique advantages. While some may wonder if the company is leveraging semiconductor technology, Mu clarifies that Hsinchu offers a robust ecosystem of precision equipment manufacturers and cross-disciplinary talent from institutions like NTHU and National Yang Ming Chiao Tung University (NYCU). This environment is ideal for a company focused on developing advanced microfluidic hardware and recruiting interdisciplinary researchers.
However, the commercial landscape for pharmaceuticals is centered in Nangang, a district in eastern Taipei where many drug development companies are located. To maintain proximity to its clients, Fluidiconic Bio plans to establish a dedicated commercial service laboratory in Nangang, complementing its manufacturing and R&D operations in Hsinchu.
A Services-Driven Approach to Market Entry
Fluidiconic Bio’s market strategy prioritizes services over equipment sales, focusing on the needs of pharmaceutical companies. These firms often prefer not to invest in specialized lab hardware; instead, they seek data without the burden of additional capital costs or staffing.
The company’s model resembles that of a contract research organization (CRO). Clients submit their drug candidates and tumor model specifications, and Fluidiconic Bio conducts the necessary assays, providing comprehensive reports. “The client doesn’t have to build the instrument or hire a team to maintain it,” Mu explains. “This approach lowers the barrier to adoption and accelerates their decision-making process.”
Challenges Ahead in the U.S. Market
Having joined Plug and Play’s accelerator program in late 2024, Fluidiconic Bio is preparing for its first exposure to the U.S. market at the upcoming summit. This opportunity is critical for establishing the American infrastructure necessary for its business model, including partnerships with local Biohubs or lab partners, forming relationships with distributors and research centers, and connecting with other service providers.
However, the company faces significant challenges as it navigates this transition. Regulatory ambiguity with the FDA regarding non-animal models poses a barrier. While recent guidance has been favorable, a standardized pathway for organ-chip platforms in drug applications remains elusive. Additionally, the entrenched practices within large pharmaceutical firms create resistance to change, as switching from traditional animal studies requires altering established workflows and risk assessments.
Building brand recognition will also be crucial. Fluidiconic Bio enters a market with established players and must work diligently to gain credibility with pharma procurement teams and the broader research community.
Conclusion
As Fluidiconic Bio prepares for its debut at the Plug and Play Summit, it stands at the intersection of innovation and opportunity. The startup’s tumor-on-a-chip technology promises to reshape the landscape of cancer drug testing, offering a glimpse into a future where precision medicine is guided by more relevant and human-centric data. With determination and strategic partnerships, Fluidiconic Bio may well become a key player in the evolution of drug development.
- Fluidiconic Bio is a Taiwanese startup focused on cancer drug testing using advanced microfluidic technology.
- The startup’s platform, MedSelect, combines 3D co-culture chips with mid-throughput workflows for enhanced data quality.
-
The company emphasizes a service-driven approach, enabling pharma clients to access data without significant capital investment.
Read more → www.digitimes.com